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The proapoptotic activity of the transcription factor p53 critically depends on the 
phosphorylation of serine 46 (p53S46P). Here, we show that syncytia containing p53S46P 
could be detected in lymph node biopsies from human immunodeficiency virus (HIV)-1 carriers, 
in the brain of patients with HIV-1–associated dementia and in cocultures of HeLa expressing 
the HIV-1 envelope glycoprotein complex (Env) with HeLa cells expressing CD4. In this latter 
model, cell death was the result of a sequential process involving cell fusion, nuclear fusion 
(karyogamy), phosphorylation of serine 15 (p53S15P), later on serine 46 (p53S46P), and 
transcription of p53 target genes. Cytoplasmic p38 mitogen-activated protein kinase (MAPK) 
was found to undergo an activating phosphorylation (p38T180/Y182P [p38 with phosphorylated 
threonine 180 and tyrosine 182]) before karyogamy and to translocate into karyogamic nuclei. 
p38T180/Y182P colocalized and coimmunoprecipitated with p53S46P. Recombinant p38 
phosphorylated recombinant p53 on serine 46 in vitro. Inhibition of p38 MAPK by 
pharmacological inhibitors, dominant-negative p38, or small interfering RNA, suppressed 
p53S46P (but not p53S15P), the expression of p53-inducible genes, the conformational 
activation of proapoptotic Bax and Bak, the release of cytochrome 
 
c
 
 from mitochondria, and 
consequent apoptosis. p38T180/Y182P was also detected in HIV-1–induced syncytia, in vivo, in 
patients’ lymph nodes and brains. Dominant-negative MKK3 or MKK6 inhibited syncytial 
activation of p38, p53S46P, and apoptosis. Altogether, these findings indicate that p38 MAPK-
mediated p53 phosphorylation constitutes a critical step of Env-induced apoptosis.
 
Viral infection can result into apoptosis, in par-
ticular at late stages of the viral life cycle when
viral spreading and/or subversion of the host’s
immune system can serve the virus’ purpose. In
accord with this general rule, HIV-1 encodes
for a variety of different proteins that can induce
apoptosis (1–3). To reveal the apoptogenic effect
of some, clinically important HIV-1–encoded
protein such as Vpr (4), it is required to take
advantage of so called pseudotyped viruses, that
is genetically modified HIV-1 strains in which
the endogenous envelope glycoprotein complex
(Env) gene has been replaced by nonapoptogenic
Env proteins from other viruses (4, 5). This un-
derscores the notion that Env is, at least in
vitro, the principal apoptosis-inducing protein
encoded by HIV-1 (6–9).
The Env glycoprotein precursor protein
(gp160) undergoes proteolytic maturation to
gp41 (membrane inserted) and gp120 (mem-
brane inserted or shed from the cell surface).
Soluble gp120 can stimulate proapoptotic signal
via an action on chemokine receptors (CXCR4
for lymphotropic Env variants, CCR5 for mono-
cytotropic Env variants; 9–11), pertussis toxin–
sensitive G proteins (11), the p38 mitogen-
activated protein kinase pathway (12), and/
or a rapid cytosolic Ca
 
2
 
 
 
 increase (13). The
membrane-bound gp120–gp41 complex ex-
pressed on the surface of HIV-1–infected cells
can induce apoptosis via interaction with un-
infected cells expressing the receptor (CD4)
and the chemokine coreceptor CXCR4. Al-
though this interaction can signal for apoptosis
via a transient cell-to-cell contact (14), in most
instances, this interaction induces cellular fusion
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(cytogamy; 6, 7, 15) followed by nuclear fusion (karyogamy)
within the syncytium (16). This nuclear fusion is the expres-
sion of an abortive entry into the mitotic prophase stimu-
lated by the transient activation of the cyclin B–dependent
kinase-1 (Cdk1; 17), accompanied by the permeabilization
of the nuclear envelope, the nuclear translocation of mam-
malian target of rapamycin (mTOR), the mTOR-mediated
phosphorylation of p53 on serine 15 (p53S15P; 18), the p53-
mediated transcription of proapoptotic proteins including
Puma (19) and Bax (18), Puma-dependent insertion of Bax
into mitochondrial membranes (19), and finally Bax-medi-
ated mitochondrial release of cytochrome 
 
c
 
 with subsequent
caspase activation (20).
Several observations suggest that p53 acts as an essential
transcription factor in the apoptotic process elicited by HIV-1
Env. First, the activating phosphorylation of p53 on serine 15
Figure 1. Phosphorylation of p53 on S46 (p53S46P) in HIV-1 
infection in vivo and Env-elicited syncytium formation in vitro. 
(A) p53S46P in lymphoid tissue. Lymph node biopsies from an untreated 
HIV-1–infected patient or an uninfected individual (control) were stained 
with an antiserum recognizing p53S46P. The insert shows a bona fide syn-
cytium positive for p53S46P. Note that the percentage of p53S46P  cells 
in HIV-1–infected, untreated individuals was 75   12 (x   SEM, n 10) in 
the T cell area, it was  1% in uninfected controls (n   5). (B) p53S46P  
PBMC, as determined by immunocytochemistry on PBMC from uninfected 
controls (n   5), untreated patients with viral loads  105 copies/ml (n   8) 
and patients under HAART with undetectable virus titers (n   10). Results 
are means   SD. (C) Correlation between the frequency of p53S46P  
PBMC and viral load among untreated HIV-1 carriers. (D) p53S46P in 
multinuclear cells from the frontal cortex with HIV-1–associated demen-
tia. Note that such p53S46P  cells were not found in control brains (from 
noninfected individuals, n   10), yet were found in 17 out of 17 cases of 
HIV-1–associated dementia. (E and F) p53S15P and p53S46P in syncytia 
generated by coculture of HeLa cells expressing HIV-1 Env and HeLa cells 
expressing CD4. Representative examples of p53S15P  p53S46P  (E) 
and p53S15P  p53S46P  (F) cells, 36 h after beginning of coculture, are 
shown. No p53S15P  p53S46P  were detectable and all syncytia positive 
for p53S15P or p53S46P exhibited karyogamy (nuclear fusion), as detect-
able by staining with Hoechst 33342. (G) Quantitation of the frequency of 
syncytia with positive and negative staining for p53S15P or p53S46P, as 
determined in C and D. Results are means of three experiments   SD. 
(H) Effect of different inhibitors on p53S15P and p53S46P in Env-elicited 
syncytia. During coculture (36 h), HeLa Env and HeLaCD4 cells were incu-
bated in the presence of the Cdk1 inhibitor roscovitine, the mTOR inhibitor 
rapamycin, the p53 inhibitor cyclic  -pifithrin, and the pan-caspase inhib-
itor Z-VAD.fmk (N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone), 
followed by analysis of karyogamy, p53S15P, p53S46P, and nuclear apop-
tosis. Results are means   SD of three independent experiments. Asterisks 
indicate significant (P   0.01, paired Student’s t test) inhibitory effects. 
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is found in lymphocyte (21) or monocyte (17) cultures in-
fected with HIV-1 in vitro, in lymph node biopsies from
HIV-1–infected donors (18), as well as peripheral blood
mononuclear cells of HIV-1–infected individuals, correlating
with viral load (17). p53 was also found to accumulate in the
cortex of patients with HIV-associated dementia (22, 23).
Second, transfection with dominant-negative (DN) p53 mu-
tants or treatment with a pharmacological p53 inhibitor, cy-
clic pifithrin-
 
 
 
 (24), prevents the Env-induced up-regulation
of Bax and thus retards syncytial cell death in vitro (17, 18).
Similarly, neurons and microglia cells from p53
 
 
 
/
 
 
 
 mice are
resistant against the lethal effect of recombinant gp120 (23).
Third, transcriptome analyses performed on HIV-1–infected
cultures revealed the induction of p53 target genes including
Bax (21, 25), and the p53-target gene Puma was found to be
up-regulated in lymph nodes and peripheral blood mononu-
clear cells from HIV-infected individuals (19).
The activation of the mitochondrial death pathway by
p53 involves transcriptional (26) and perhaps nontranscrip-
tional effects (27). The transcriptional activity of p53 and its
preferential activation on apoptosis-inducing (rather than
cell cycle–arresting) genes depends on a series of posttran-
scriptional modifications, one of which is phosphorylation of
p53 on serine 46 (p53S46P; 28, 29). This activating phos-
phorylation can be mediated by ataxia telengiectasia–
mutated protein (presumably in an indirect fashion; 30) and
directly by homeodomain-interacting protein (HIP) kinase-2
(31, 32), and perhaps p38 MAPK (33, 34), although this lat-
ter interaction has not yet been shown to be direct. To fur-
ther characterize the role of p53 in HIV-1 Env-induced ap-
optosis, we therefore decided to investigate the implication
of p53S46P and putative p53S46P kinases in the death pro-
cess. Here, we describe that p53S46P mediated by p38
MAPK is a critical event of Env-induced apoptosis.
 
RESULTS
Phosphorylation of p53 on serine 46 (p53S46P) elicited by 
HIV-1 Env and HIV-1 infection in vitro and in vivo
 
Lymph node biopsies from several untreated HIV-1–infected
individuals were found to contain a substantial fraction of
cells whose nucleus stained positively with a phosphoneo-
epitope-specific antibody recognizing p53S46P. Frequently,
such p53S46P
 
 
 
 cells contained several nuclei and thus were
bona fide syncytia. In contrast, no such p53S46P
 
 
 
 staining
was found in biopsies from healthy controls (Fig. 1 A).
p53S46P
 
 
 
 cells were also found among circulating PBMC
from HIV-1–infected patients, yet disappeared after success-
ful antiretroviral therapy (Fig. 1 B). Among untreated pa-
tients, a positive correlation between the frequency of
p53S46P
 
 
 
 PBMC and viral titers was found (Fig. 1 C).
Multinuclear cells expressing p53S46P were also observed in
postmortem brain sections from patients with HIV-1–associ-
ated dementia, in 17 out of 17 cases (Fig. 1 D). Such
p53S46P-expressing multinuclear cells stained positively for
the HIV-1 antigen p24 (unpublished data), suggesting that
they result from direct HIV-1 infection (35). Multinuclear
cells were absent in HIV-1–infected patients without neuro-
logical symptoms (
 
n
 
 
 
 
 
 10), as well as in uninfected controls
(36). Moreover, syncytia formed by coculture of Env-trans-
fected HeLa cells with a CD4–CXCR4-expressing HeLa
cell line exhibited p53S46P, as detectable by two different
methods, namely immunofluorescence staining (Fig. 1, E–G)
and immunoblotting (see Fig. 3 D and Fig. 9 B). Double
staining experiments revealed that all p53S46P
 
 
 
 syncytia
Figure 2. Identification of p38 MAPK as a putative p53 S46-
phosphorylating enzyme. (A) Screening of putative p53-phosphorylating 
kinases. HeLa Env/CD4 cocultures (36 h) were performed in the presence 
of the indicated inhibitors (500  M caffeine, 5  M PD98059, and 100 nM 
of the SB series), and the frequency of p53S46P  syncytia or single cells 
(SC) was determined by immunofluoresence as in Fig. 1 C. (B) Effect of 
HIPK2-antisense oligonucleotide on p53S46P. HeLa Env/CD4 were trans-
fected with a HIPK2-antisense oligonucleotide or a scrambled control oligonu-
cleotide for 24 h before initiation of coculture and then cocultured for 
36 h, followed by scoring of p53S46P  syncytia. (C and D) Dose response 
of the inhibitory effect of SB203580. HeLa Env/CD4 cocultures (36 h) were 
performed in the presence of variable concentrations of SB203580, and 
the frequency of p53S46P  (C) and karyogamic syncytia (D) was deter-
mined. Results are means   SD of three determinations, and asterisks 
indicate significant (P   0.01) effects. 
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were p53S15P
 
 
 
 (Fig. 1 F), whereas some p53S15P
 
 
 
 syncytia
were p53S46P
 
 
 
 (Fig. 1 E), and very few if any p53S15P
 
 
 
p53S46P
 
 
 
 (Fig. 1 G). This suggests that p53 is first phos-
phorylated on S15 and then on S46, as corroborated by
kinetic studies (see Fig. 3 D). Inhibition of Cdk1 (with ros-
covitine) and mTOR (with rapamycin), which both inhibit
karyogamy (17), both reduced p53S15P and p53S46P. In
contrast, inhibition of p53-mediated transactivation (with
cyclic pifithrin-
 
 
 
) and apoptotic caspase activation (with
Z-VAD.fmk [
 
N
 
-benzyloxycarbonyl-Val-Ala-Asp-fluoro-
methylketone]) had no effect on p53S15P and p53S46P (Fig. 1
H). As an internal control of their efficacy, all these treat-
ments significantly reduced syncytial apoptosis. Altogether,
these findings suggest that p53S15P and p53S46P occur
as functionally linked, yet sequential events, independently
from p53-mediated transcriptional effects and upstream from
apoptosis.
 
Identification of the p53S46 kinase stimulated by HIV-1 
Env as p38 MAPK
 
Inhibition of putative p53S46 kinases with caffeine (which
inhibits ataxia telengiectasia–mutated protein) (37), LY294002
(which inhibits PI3 kinases; 38), PD98059 (which inhibits
ERK1/2; 39), or transfection with an antisense oligonucle-
otide designed to down-regulate the expression of HIP ki-
nase-2 (31), had no effect on the frequency of p53S46P
 
 
 
syncytia (Fig. 2, A and B) and did not reduce the propensity
of syncytia to undergo apoptosis (unpublished data). In strict
contrast, SB203580, an inhibitor of p38 MAPK (40),
strongly reduced p53S46P. The inhibition of p53S46P was
also observed with another p38 MAPK inhibitor, SB202190
(41), but not with the inactive analogue SB202474 (Fig. 2
A). The inhibition of p53S46P with SB203580 was near-to-
optimal at 100 nM (Fig. 2 C), that is at a concentration re-
ported to be specific for p38 MAPK (40). At this dose,
SB203580 had no effect on syncytium formation (unpub-
lished data) and karyogamy (Fig. 2 D). Using an antibody
that recognizes phosphorylated p38 MAPK (p38T180P–
Y182P), we detected activate p38 in HeLaEnv–CD4 cocul-
tures. At the prekaryogamic stage, p38T180P–Y182P was
confined to the cytoplasm. During karyogamy, however,
p38T180P–Y182P concentrated in the nucleus (Fig. 3 A).
The relocalization of p38T180P–Y182P correlated with the
phosphorylation of one of its nuclear targets, ATF-2 (42), on
T271 (ATF-2 with phosphorylated tyrosine 271 [ATF-
2T271P]; Fig. 3 B), suggesting that nuclear p38 MAPK is
truly active. Syncytia became p38T180P–Y182P
 
 
 
 (Fig. 3 C)
and ATF-2T271P
 
 
 
 (unpublished data) before their mito-
chondria released cytochrome 
 
c
 
 and their nuclei condensed,
as confirmed by kinetic analyses (Fig. 3 D). Thus, p38 MAPK
activation occurs before apoptosis. Importantly, p38T180P–
Y182P was also detected in HIV-1–infected cultures, shortly
upon productive infection (Fig. 4 A), in a fraction of lymph
node cells from untreated HIV-1–infected donors with high
viral titers (Fig. 4 B), in PBMC from untreated HIV-1 carri-
ers, correlating with viral load (Fig. 4 C), as well as in syncy-
Figure 3. Phosphorylation of p38 MAPK and ATF-2 in Env-elicited 
syncytia. (A and B) Detection and subcellular localization of p38 MAPK 
phosphorylated on T180/Y182 (p38T180/Y182P) and ATF-2 phosporylated 
on T271 (ATF-2T271P). HeLa Env/CD4 cocultures (Syn., 36 h) or freshly 
mixed single cell (SC) suspensions were subjected to immunoblot detec-
tion of p38 (irrespective of its phosphorylation status), p38T180/Y182P 
(A), or ATF-2T271P (B). Moreover, immunofluorescence stainings for the 
detection of p38T180/Y182P (A) or ATF-2T271P (B) were performed and 
representative examples of prekaryogamic (preKG) and karyogamic (KG) 
syncytia are depicted. Note that p38T180/Y182P is cytoplasmic in prekaryo-
gamic syncytia and nuclear in karyogamic syncytia. (C and D) Temporary rela-
tionship of p38T180/Y182P with regard to apoptosis. Double staining ex-
periments revealed that nuclear p38T180/Y182P was detectable whereas 
cytochrome c was still retained in a punctate cytoplasmic (mitochondrial) 
localization (C). Kinetic analyses indicate that nuclear p38T180/Y182P 
accumulation correlates with p53S46P (D) yet occurred before cytochrome c 
release and nuclear chromatin condensation. 
JEM VOL. 201, January 17, 2005
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tia, present in cortical brain sections of patients with HIV-
1–associated dementia (Fig. 4 D). Altogether these data indi-
cate HIV-1–induced p38 MAPK activation in vitro and
in vivo. Confocal two-color immunofluorescence micros-
copy indicated that a fraction of activated p38 (p38T180P–
Y182P) colocalized with p53S46P, in the nucleus of karyo-
gamic HeLa syncytia (Fig. 5 A). p38T180P–Y182P also
coimmunoprecipitated with p53 (Fig. 5 B). As a formal
proof of the capacity of p38 to phosphorylate p53, recombi-
nant p38 was mixed with recombinant p53, resulting in p53
phosphorylation on S46 and S15, in a SB203580-repressible
fashion (Fig. 5 B). These data support the contention that
p38 MAPK is indeed the Env-elicited kinase that phosphor-
ylates p53 on S46.
 
Selective inhibition of p53S46P abolished p53-mediated 
transcription and apoptosis in Env-elicited syncytia
 
As shown above, specific inhibition of p38 MAPK by
SB203580, used at a concentration of 100 nM, fully pre-
vents the apoptogenic phosphorylation of p53 on S46 in
HeLa Env–CD4 syncytia. At this dose, however, SB203580
had no effect on the syncytial accumulation of cyclin B (un-
published data) and thus did not prevent karyogamy (Fig. 6
A). Very similar results, that is inhibition of ATF-2T271P
and p53S46P (but not p53S15P), were obtained when p38
MAPK was neutralized by transfection with a DN p38 mu-
tant (43) (Fig. 6 B) or when p38 MAPK was knocked down
with a p38-specific small interfering RNA (siRNA; Fig. 6,
C and D). Although p38 suppression by itself did not in-
hibit p53S15P (Fig. 6, A–C), the combined inhibition of
p38 (with SB203580) and another established p53S15 ki-
nase, mTOR (with rapamycin), had a synergistic inhibitory
effect (Fig. 6 E), suggesting that p38 MAPK has some
Figure 4. Detection of activated p38 MAPK (p38T180/Y182P) in 
HIV-1 infection. (A) In vitro induction of p38T180/Y182P. C8166 cells 
were infected with a clinical HIV-1 isolate as detailed in the Materials and 
Methods section. The amount of p24 was quantified by ELISA in the super-
natants of cultures. (B) Presence of p38T180/Y182P in lymph node biopsies 
from a freshly diagnosed, untreated HIV-1 carrier with viral loads  105 
copies/ml. 83   8% (x   SD, n   6) of the lymph node cells from such 
HIV-1 carriers were scored as positive for p38T180/Y182P, whereas control 
biopsies from noninfected individuals lack p38T180/Y182P ( 1% positive 
cells, n   5). The insert shows a putative syncytium. (C) Correlation between 
the frequency of p38T180/Y182P  PBMC and viral titers in untreated HIV-1 
carriers. (D) Detection of p38T180/Y182P in cortical brain sections of indi-
viduals with clinically manifest HIV-1–associated dementia. The insert 
shows a multinucleated p38T180/Y182P  cell. Such images have been 
obtained in 17 different individuals with HIV-1–associated dementia but 
not in 10 different control subjects. Among multinucleated cells, 63   
19% (x   SD, n   9) were found to express p38T180/Y182P.
Figure 5. Direct phosphorylation of p53 on S46 by p38 MAPK. 
(A) Coimmunolocalization of p38T180/Y182P and p53S46P. HeLa Env/CD4 
cocultures (36 h) were subjected to simultaneous detection of p38T180/Y182P 
and p53S46P with monoclonal mouse and polyclonal rabbit antibodies, 
revealed by red and green fluorescence, respectively. Note the significant 
coimmunolocalization (yellow). (B) Coimmunoprecipitation of p38T180/Y182P 
and p53. Extracts from HeLa Env/CD4 cocultures were subjected to immu-
noprecipitation (IP) of p38T180/Y182P, followed by immunodetection of 
p53 in the immunoprecipitate. (C) Direct phosphorylation of p53 by p38 
MAPK in vitro. Recombinant p38 and p53 were mixed together in the 
presence of 1 mM ATP and in the absence or presence of the p38 MAPK 
inhibitor SB203580 (100 nM), followed by immunodetection of p53 (phos-
phorylated or unphosphorylated), p53S15P, and p53S46P. These experi-
ments were repeated twice, yielding similar results. 
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p53S15 kinase activity in vivo, in accord with the in vitro
data (Fig. 5 C).
Next, we transfected HeLa Env and HeLa CD4 cells
with a p53-inducible green fluorescent plasmid (GFP) re-
porter gene, followed by coculture of the two cell lines to
generate syncytia, which express GFP (whereas single cells
remain GFP negative). The two p38 MAPK inhibitors
(SB203580 or SB202190) and DN p38 strongly inhibited
the syncytial expression of p53-inducible GFP (Fig. 7 A)
and of a p53-inducible luciferase reporter construct (Fig. 7
B), respectively. Thus, the selective inhibition of p53S46P
(without any effect on p53S15P) suffices to block the trans-
activating function of p53, at least in this system. Because
apoptosis of Env-elicited syncytia depends on p53-medi-
ated transcriptional effects (as described in the introduction),
p53S46P inhibition should result in the interruption of the
lethal signal transduction cascade. Accordingly, SB203580
and DN p38 inhibited the conformational activation of Bax
and Bak that normally occurs in untreated syncytia (detect-
able by immunofluorescence with antibodies recognizing
the exposed NH
 
2
 
 termini of Bax or Bak), the release of cy-
tochrome 
 
c
 
 from mitochondria (detectable by immunostain-
ing) and apoptotic nuclear condensation (Fig. 7, C and D).
p38 inhibition also abolished the p53-dependent induction
of the proapoptotic Bax/Bak activator Puma, whereas inhib-
iting syncytial apoptosis (Fig. 7 E). Altogether, these data un-
derscore the critical apoptogenic role of p38 MAPK-medi-
ated p53S46P for Env-induced apoptosis.
 
Upstream signaling events leading to p38 MAPK activation
 
In a further series of experiments, we addressed the question
as to whether cell fusion per se would be sufficient to elicit
p38 activation and apoptosis or whether Env-mediated sig-
nal received via CD4 and CXCR4 would be required for
this process. HeLa CD4 and HeLa Env cells fused with poly-
ethylene glycol (PEG) still exhibited a significant level of p38
MAPK phosphorylation when C34 (an inhibitor of the
interaction of Env with the CD4–CXCR4 complex) was
added into the system. Similarly, PEG-enforced homotopic
fusion of HeLa CD4 cells or HeLa Env cells resulted in p38
activation, p53S46P and apoptosis (Fig. 8). Thus, hetero-
topic interactions between Env and CD4–CXCR4 are not
absolutely required for the activation of p38. Nonetheless,
the interaction between Env and CD4–CXCR4 yields a
higher level of p38 activation than when it is blocked, either
by the C34 peptide or by the elimination of either CD4 or
Env from the system (Fig. 8). In a further series of experi-
ments, Env-elicited syncytia were found to exhibit an ac-
tivating phosphorylation of the MAPK kinase MKK3 or 6
on S189 or S207, respectively, using a bispecific antibody
(which recognizes phosphorylated forms of either MKK 3
and 6; Fig. 9 A). Transfection with DN mutants of MKK3
or MKK6 inhibited the appearance of p38T180P–Y182P
and p53S56P in Env-elicited syncytia (Fig. 9 B). Moreover,
DN MKK3 or DN MKK6 abolished the transcriptional ac-
tivity of p53 in this system (Fig. 9 C) and suppressed all mi-
tochondrial and nuclear manifestation of apoptosis, yet had
no effect on karyogamy and p53S15P (Fig. 9 D). Thus,
MKK3/6 is indispensable for p38 MAPK activation, p53
phosphorylation on S46 (but not S15), and p53-dependent
apoptosis. Altogether, these data point to a cascade in which
syncytium formation results in the activation of the lethal
MAP kinase cascade.
 
DISCUSSION
 
The data shown in this paper establish that p38 MAPK can
phosphorylate p53S46P, thereby triggering the proapoptotic
Figure 6. Specific requirement of p38 MAPK for p53 phosphoryla-
tion on S46 in Env-elicited syncytia. (A–C) Effect of p38 MAPK kinase 
inhibition of phosphorylation events detected by immunofluorescence. 
Three different methods of p38MAPK kinase inhibition were employed: 
addition of a chemical inhibitor (100 nM SB203580) from the beginning of 
coculture lasting 36 h (A), transfection with a DN p38 mutant 24 h before 
initiation of coculture (B, control/transfection with vector only), and p38-
specific siRNA 24 h before coculture (C, control/irrelevant siRNA). Results 
are means of three independent experiments (x   SD, n   3) and asterisks 
indicate significant (P   0.01) differences with respect to controls. 
(D) Confirmation of the effect of p38 siRNA by immunoblot. Syncytia 
obtained by cocultures as in C were subjected to immunoblot detection 
of p38 MAPK, p53S46P, and GAPDH. (E) Effect of the combined inhibition 
of p38 MAPK and mTOR on p53S15P. Cells were cultured in the presence of 
SB203580 (100 nM) and/or rapamycin (1  M) for 30 h, and the number of 
p53S15P  cells was scored by immunofluorescence. Asterisks indicate sig-
nificant (P   0.01) inhibitory effects. 
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transactivating function of p53. This notion is based on the
strong correlation between the activatory p38 phosphoryla-
tion (p38T180P–Y182P) and p53 phosphorylaton on S46
(p53S46P), in Env-elicited syncytia generated in vitro (Figs.
1 and 3), in HIV-1–infected cultures of CD4
 
 
 
 cells (Fig. 4
A), as well as in lymph nodes, PBMC, and cortical sections
from HIV-1–infected individuals (Fig. 1, A–D and Fig. 4,
B–D). Inhibition of p38 MAPK by a variety of different
techniques (pharmacological agents, siRNA, transfection with
DN mutants of either p38 MAPK or MKK3/6) prevented
p53S46P and blocks apoptosis, thus establishing the cause
and effect relationship between p38 MAPK activation,
p53S46P, and subsequent cellular demise (Figs. 2 and 5–8).
It appears plausible that p38 phosphorylates p53 in a direct
fashion because both proteins colocalized and coimmuno-
precipitated in Env-elicited syncytia (Fig. 5, A and B) and
because recombinant p38 MAPK phosphorylated recombi-
nant p53 on S46 in vitro (Fig. 5 C). As a side observation,
p38 MAPK also phosphorylated p53 on S15 (Fig. 5 C), but
this reaction is likely to play a minor role in vivo, given that
p38 MAPK inhibition alone did not reduce p53S15P and
only became effective when the principal p53S15 kinase op-
erating in this system, mTOR (17, 18), was also inhibited
(Fig. 6 E).
Figure 7. Abolition of p53-mediated transcription and apoptosis 
induction by inhibition of p38 MAPK. (A) Effect of chemical p38 MAPK 
inhibitors on Env-induced p53-mediated transcription within syncytia. A 
p53-inducible GFP reporter gene was transfected into HeLa Env/CD4 cells 
24 h before coculture for 36h, resulting in expression of GFP mainly within 
syncytia, but not single cells (left panel). The effect of the p38 MAPK inhib-
itors SB203580 and SB202190 (as well as that of the ineffective control 
compound SB202474) is shown in the right panel. (B) Effect of DN p38. 
HeLa Env/CD4 cells were transfected with a p53-inducible luciferase reporter 
construct (p53-Luc), a noninducible luciferase construct (pTA-Luc), with 
p38 DN or its empty vector, 24 h before coculture, followed by coincubation 
of HeLa Env and HeLa CD4 cells for 36 h and determination of luciferase 
activity. (C and D) Effect of pharmacological p38 MAPK inhibiton (C) or DN 
p38 (D) on the immunofluorescence-detectable exposure of the Bax or 
Bak NH2 termini, the mitochondrial release of cytochrome c, and Hoechst 
33342-detectable chromatin condensation 36 h after syncytium formation. 
Note that these parameters are largely negative in single cells ( 5%). 
(E) Effect of p38 MAPK knock-down by siRNA. Cells were subjected to 
siRNA 24 h before coculture for 36 h (syncytia, Syn) or separate coculture 
for 36 h (single cells, SC), and the expression of p38 MAPK, PUMA, and Bax 
was monitored by immunoblot. The frequency of apoptotic cells was de-
termined among single cells and syncytia by Hoechst 33312 staining and 
fluorescence microscopy.
Figure 8. Cell fusion for activation for p38 MAPK cascade. HeLa Env 
and HeLa CD4 cells were fused in the indicated heterotopic or homotopic 
combination with polyethyleneglycol, followed by coculture for 36 h in 
the presence or absence of C34 (which inhibits the interaction between 
CD4 and Env). Then, the frequency of syncytia exhibiting activating phos-
phorylation of p38, p53, and mitochondrial or nuclear characteristics of 
apoptosis was determined by immunofluorescence staining. Double aster-
isks indicate significant effects of C34 as compared with HeLa Env plus 
HeLa CD4 cells fused with PEG. Single asterisks show significant (P   0.01, 
Student’s t test) differences between the PEG-enforced fusion of HeLa 
CD4 or HeLa Env cells, as compared with the spontaneous fusion between 
HeLa Env and HeLa CD4 cells.P53 IN HIV-1 INFECTION | Perfettini et al. 286
An interesting problem arises from the fact that p38
MAPK activation is a frequent stress response, which nor-
mally does not lead to cell death (44–46). One mechanism of
regulation could be the intracellular localization of p38
MAPK. Whereas p38T180P–Y182P is confined to the cyto-
plasma, early after syncytial formation, it later moves to the
nucleus, when the nuclear envelope loses its barrier function
due to the action of the mitotic Cdk1–cyclin B complex
(Fig. 3 A). Hence, inhibition of Cdk1–cyclin B prevents
the nuclear relocalization of p38T180P–Y182P (unpublished
data) and concomitantly prevents the phosphorylation of nu-
clear p38 MAPK targets such as ATF-2 and p53 (Fig. 1 G).
Thus, a combination of aberrant cell cycle regulation and ki-
nase activation may have novel effects when p38 MAPK
gains access to the nucleus and hence to substrates from
which it usually is separated. In this context, it is intriguing
that p38 MAPK can actually mediate a G2/M arrest in re-
sponse to different cellular stressors including DNA damage
(47, 48) and osmotic stress (49), presumably through inacti-
vation of the cell cycle regulator CDC25C phosphatase and
its downstream target Cdk1. However, in the paradigm of
syncytial apoptosis studied here, inhibition of p38 MAPK
did not release the cells from G2/M arrest and thus did nor
provoke an increase in syncytial divisions.
It is important to note that p38 MAPK is a pleiotropic ki-
nase that, in the context of HIV-1 infection, is not only in-
volved in the apoptotic cascade triggered by syncytium for-
mation. It has been shown that pharmacological inhibition of
p38 can actually reduce HIV-1 replication in vitro, via an un-
known mechanism (50, 51). The data contained in this paper
suggest that, in addition, p38 may be cardinal for the trans-
mission of lethal signals elicited by Env, even in the absence
of a virus, that is in the context of bystander killing. Thus,
p38 might become an attractive (therapeutic or experimental)
target, either for suppressing HIV-1 replication or for reduc-
ing deleterious host responses to viral products such as Env.
MATERIALS AND METHODS
Cells and culture conditions.  HeLa cells stably transfected with the
Env gene of HIV-1LAI/IIIB (HeLa Env) and HeLa cells transfected with CD4
(HeLa CD4) were cocultured at a 1:1 ratio, in Dubelcco’s modified Eagle’s
medium supplemented with 10% FCS, L-glutamine, in the absence or pres-
ence of 1  M roscovitin (Calbiochem-Novabiochem), 1  M rapamycin
(Sigma-Aldrich), 10  M cyclic pifithrin- , 100  M ZVAD (Bachem), 500
 M caffeine (Calbiochem-Novabiochem), 1  M LY294002 (Sigma-Ald-
rich), 5  M PD98059 (Calbiochem-Novabiochem), p38 MAPK inhibitors
(SB203580 and SB202190), and an inactive analogue of p38 MAPK inhibi-
tors, SB202474 (Calbiochem-Novabiochem). HeLa CD4 or/and HeLa Env
were also cultured on coverslips and were fused with PEG, as described pre-
viously (17–20).
Plasmids, transfection, and p53-mediated transcription activity.
HeLa CD4 and HeLa Env cells were transfected with the p53 luciferase re-
porter construct p53-Luc alone (Mercury pathway profiling system from
CLONTECH Laboratories, Inc.; 1  g DNA) or together with the control
Figure 9. Activation of MKK3/6 upstream of p38 MAPK in Env-
elicited syncytia. (A) Detection of the activated, phosphorylated form of 
MKK3/6 (MKK3/6 S89/207P) in separate or cocultures of HeLa Env and 
HeLa CD4 cells. (B) Effect of DN MKK3 and MKK6 on the phosphorylation 
of p38 and p53. HeLa Env/CD4 cells were transfected with the indicated 
construct (or vector only; control [Co.]), 24 h before coculture for 36 h, 
and the presence of the indicated antigens was determined. (C) Effect of 
DN MKK3 and MKK6 on p53-mediated transactivation. Cells were simulta-
neously transfected with p53-inducible GFP, in combination with empty 
vector, DN MKK3 or DN MKK6, 24 h before coculture and the frequency of 
GFP-positive syncytia was scored after 36 h of coculture. (D) Effect of DN 
MKK3 and MKK6 on the apoptotic cascade elicited by Env. The indicated 
phenomena were detected by immunofluorescence, in three independent 
experiments. Results are means   SD (n   3), and asterisks indicate sig-
nificant (P   0.01) inhibitory effects, as compared with vector-only trans-
fected controls.JEM VOL. 201, January 17, 2005 287
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luciferase reporter construct or with the p38 dominant negative mutant
(p38DN; reference 43; 1  g DNA). Transfections were performed using 2
 l Lipofectamine 2000 (InVitrogen) 24 h before fusion. Luciferase activity
was measured after 24 h of coculture using the luciferase reporter assay kit
from CLONTECH Laboratories, Inc. Transfections of a p53-responsive
enhanced GFP (19; gift from Klas Wiman, Karolinska Hospital, Stockholm,
Sweden) with pcDNA3.1 vector alone (control) (1  g DNA) or with a DN
MKK3 mutant (pcMKK3DN S189A/T193L) or/and with MKK6 DN
plasmids (pcMKK6DN S207A/T211L; reference 52; 1  g DNA) were per-
formed 24 h before coculture of HeLa CD4 and HeLa Env cells, using
transfection’s protocol described above. The frequency of GFP-expressing
cells was assessed by immunofluorescence.
In vitro kinase assays. Kinase reactions were performed in 50  l of kinase
buffer (50 mM Hepes, pH 7.4, 25 mM MgCl2, 25 mM  -glycerophosphate,
2 mM DTT and 0.1 mM Na3VO4) containing 1  g of an active GST-p38
recombinant protein (Chemicon), 1 mM ATP and 2  g of fusion protein
corresponding to the full-length p53 protein of human origin as substrate
(Santa Cruz Biotechnology, Inc.). Reactions were performed for 30 min at
30 C and stopped by adding 50  l of 2  sample buffer and boiling for 5 min.
Samples were resolved by SDS-PAGE. The phosphorylation status of p53
was monitored by immublotting with p53S15P and p53S46P antibodies.
Immunoblot and immunoprecipitation.  Total cellular proteins were
extracted in lysis buffer (50 mM Tris, pH 7.5, 250 mM NaCl, 0.1% NP-40,
5 mM EDTA, 10 mM Na3VO4, 10 mM NaF, 5 mM DTT, 3 mM
Na4P2O7, 1 mM PMSF, 1  g/ml aprotinin, 1  g/ml leupeptin, 1  g/ml
pepstatin). Aliquots of protein extracts (30  g) were resolved by SDS-
PAGE and transferred onto nitrocellulose membranes. After incubation for
12 h with membrane blocking solution (Zymed Laboratories), membranes
were incubated with antibodies specific for p38, p38T180/Y182P [p38
with phosphorylated threonine 180 and tyrosine 182], ATF-2T271P,
p53S15P, p53S46P, and p53 (Cell Signaling Technology), Puma (US Bio-
logical), or GAPDH (mAb from Chemicon). For immunoprecipitation, ly-
sates (200  g) were incubated overnight at 4 C with affinity-purified rabbit
polyclonal antibodies specific for p38T180–Y182P. Immunocomplexes were
recovered by the addition of protein A/G–agarose beads (1 h at 4 C; Santa
Cruz Biotechnology, Inc.), washed six times with lysis buffer, and subjected
to SDS-PAGE. Immunoblot analysis was performed with a p53-specific
mAb (Santa Cruz Biotechnology, Inc.).
Immunofluorescence.  Cocultures were fixed with 4% paraformalde-
hyde/0.19% picric acid/phosphate-buffered saline for 30 min, permeabi-
lized with 0.1% SDS for 10 min, and incubated with FCS for 20 min. Rab-
bit antisera specific for p53S15P, p53S46P, p38T180/Y182P, ATF-2T271P
(Cell Signaling Technology), or the NH2 terminus of Bax (N20; Santa Cruz
Biotechnology, Inc.) were used for immunodetection in PBS containing 1
mg/ml BSA and revealed with goat anti–rabbit IgG conjugated to Alexa
568 (red) or Alexa 488 (green) fluorochromes from Molecular Probes. Cells
were also stained for the detection of the NH2 terminus of Bak (Ab1; On-
cogene Research Products), p53S15P (mAb), p38T180/Y182P (mAb; Cell
Signaling), revealed by anti–mouse IgG Alexa conjugates. To assess karyog-
amy and apoptotic chromatin condensation, cells were counterstained with
Hoechst 33342 (Molecular Probes).
Antisense constructs and RNA interference.  The inhibition of en-
dogneous HIPK2 expression was performed with HPLC-purified antisense
phosphorothioate oligonucleotides (HIPK2 antisense: 5 -CGCGGTTCAT-
GGCAACGGAGAAGGG-3 ; control: 5 -CCTCTTACCTCAGTTA-
CAATTTATA-3 ; GeneSet Oligos, Paris, France; 32). The HIPK2 or con-
trol antisense phopshorothioate oligonucleotides (100 nM) were transfected
with 2  l of Oligofectamine Reagent (Invitrogen) into HeLa CD4 and
HeLa Env, 24 h before coculture. RNA interference of p38MAPK expres-
sion was obtained using the p38 siRNA/siAB Assay Kit (Upstate Biotech-
nology), following the manufacturer’s protocol. Both HeLa CD4 and
HeLa Env cells were transfected with a pool of four selected specific
p38MAPK  siRNA duplexes or with nonspecific siRNA duplexes, 24 h
before coculture.
Patients’ samples and in vitro infection with HIV-1 isolate. Axil-
lary lymph node biopsies were obtained from healthy and HIV-1–infected
individuals (all males, mean age 36 yr, with a plasma viral load  105 copies/
ml) after informed consent. Plasma HIV-1 RNA levels were determined by
the bDNA procedure (Versant HIV RNA 3.0) according to the manufac-
turer’s instructions (Bayer). None among the HIV-1  patients received in-
terferons, glucocorticoids, was positive for hepatitis B or C, or exhibited
signs of autoimmunity. Postmortem frontal cortex sections were obtained
from 17 brains of patients with HIV-1–associated dementia (but lacking
secondary infections), 10 HIV-infected patients without neurological symp-
toms, and 3 control brains obtained from uninfected control patients. These
autopsy samples from patients enrolled in a prospective studies on HIV-
related dementia were obtained from the Institute of Pathological Anatomy,
Catholic University of Rome, School of Medicine (Rome, Italy). Biopsies
and postmortem samples were obtained in accord with the national legisla-
tion, after approval by the Institutional Review Board of the National Insti-
tute for Infectious Disease “Lazzaro Spalanzani.” After fixation with 10%
formalin and dehydration, frontal cortex samples and lymph nodes biopsies
were embedded in paraffin. Sections were then cut, deparaffinized, sub-
jected to immunocytochemistry with antibodies specific for p53S46P or
p38T180/Y182P (same antibodies as for immunofluorescence), and coun-
terstained with hematoxylin. C8166 cells (10   106) were incubated with a
clinical HIV-1 isolates (500 ng of p24) for 4 h at 37 C. After washing out
unabsorbed virus, cells (106 cells/ml) were cultured in RPMI medium con-
taining 10% FCS. Total proteins were obtained using TRIzol (Invitrogen)
and subjected to immunoblot analysis. PBMC were isolated by Ficoll/
Hypaque (Amersham Biosciences) centrifugation of heparinized blood from
healthy donors and HIV-seropositive individuals and fixed with 4% formal-
dehyde in PBS (pH 7.2) before immunohistochemical analyses.
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